Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients
- 1 January 1998
- journal article
- clinical trial
- Published by Springer Nature in Journal of Pharmacokinetics and Biopharmaceutics
- Vol. 26 (2) , 207-246
- https://doi.org/10.1023/a:1020561807903
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosisClinical Pharmacology & Therapeutics, 1997
- Discrimination between rival dosing histories.Pharmaceutical Research, 1997
- Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studiesEuropean Journal of Clinical Pharmacology, 1996
- A nonparametric subject-specific population method for deconvolution: II. External validationJournal of Pharmacokinetics and Biopharmaceutics, 1995
- A population model for the leukopenic effect of etoposidePublished by Wiley ,1995
- Experimental Design and Efficient Parameter Estimation in Preclinical Pharmacokinetic StudiesPharmaceutical Research, 1995
- Some general estimation methods for nonlinear mixed-effects modelJournal of Biopharmaceutical Statistics, 1993
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assemblyClinical Pharmacology & Therapeutics, 1989
- Pharmacokinetics of Moxonidine After Single and Repeated Daily Doses in Healthy VolunteersThe Journal of Clinical Pharmacology, 1987